Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging
Anti-PD-1 mAb and STING agonists have shown notable synergy in upregulating LAG-3 expression on TILs in HCC, which can be successfully tracked by [<sup>68</sup>Ga]Ga-NOTA-C25 PET imaging. Furthermore, integration of a triple immunotherapy regimen comprising an anti-PD-1 mAb, STING agonist, and anti-LAG-3 mAb demonstrated a significant improvement in therapeutic efficacy over dual immunotherapy approaches.
Authors
- Quan Chen (ORCID: https://orcid.org/0000-0001-6360-5953)
- Dawei Jiang (ORCID: https://orcid.org/0000-0002-4072-0075)
- Ziwei Jin (ORCID: https://orcid.org/0000-0001-8939-9799)
- Zhen Quan
- Xin Li (ORCID: https://orcid.org/0000-0002-5985-003X)
- Na Hao (ORCID: https://orcid.org/0000-0002-4527-8167)
- Yiwan Guo
- Yu Gao (ORCID: https://orcid.org/0009-0004-0271-7571)
- Chuansheng Zheng
- Bo Sun
Institutions
- Union Hospital (HK)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Hubei University (CN)
Publication Details
- Journal
- Biomarker Research
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1186/s40364-025-00820-z
- Citations
- 8
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 6.38
Funders
- National Natural Science Foundation of China